Regeneron pauses drug trial on sickest – Home Health Choices
For the second time, a examine testing an antibody drug…Latest Updates
The firm had earlier obtained approval from the Drugs Controller General of India (DCGI) to fabricate 40 mg enzalutamide in 2017 to deal with males with metastatic castration-resistant prostate most cancers (mCRPC) underneath the model identify Bdenza, BDR Pharma mentioned in a press release.
The 80 mg model is an try to cut back the capsule burden as it’s anticipated to extend the affected person compliance, it added.
“At BDR Pharma, we aim to introduce innovative treatment options that will benefit cancer patients and improve their overall standard of care. This launch further strengthens our commitment to provide affordable and accessible treatment options for patients with prostate cancer in India,” BDR Pharma CMD Dharmesh Shah mentioned.
The drug is being launched at a worth of Rs 24,480 for one pack with four strips. Each strip has 14 tablets, the corporate mentioned.
Prostate most cancers is among the main cancers in India, which often impacts males within the age group of over 65 years, the assertion mentioned.